BMO Capital Markets Says 4D Molecular Could Be 'Attractive Acquisition Target'
- ByBenzinga-
BMO Capital Markets initiated coverage on 4D Molecular Therapeutics Inc (NASDAQ: FDMT) with an Outperform rating and a price target of $50. The analyst writes that 4DMT's platform...